Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Trial Profile

A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ONC-206 (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; CNS cancer; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Medulloblastoma; Meningioma; Neuroectodermal tumours; Neuroepithelial neoplasms; Oligodendroglioma; Primitive neuroectodermal tumours; Sarcoma; Tumours
  • Focus Adverse reactions; First in man
  • Sponsors Chimerix; Oncoceutics
  • Most Recent Events

    • 01 Mar 2024 According to a Chimerix media release, the company expects to report preliminary safety and pharmacokinetic data from these trials beginning in mid-2024.
    • 01 Mar 2024 According to a Chimerix media release, the company is planning in completing ONC206 dose escalation this year
    • 04 May 2023 According to a Chimerix media release, the company expects to complet dose escalation by first half of 2024,
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top